Here you go Kelsee. The main subject is the new public enemy #1: Martin Shkreli. He seems to be an expert in alienating people. Not only is he hated by the general public but I imagine his name is being cursed in BP board rooms all over the US - shareprices of Alexion, Valeant, Allergan getting smashed!

On a serious note the article makes the point on how hard it is for the government to control drug pricing on rare indications. I also note how RVX has been thinking very carefully about pricing, and how to position itself in the market. I am confident that RVX has a very sensible pricing strategy.

http://www.forbes.com/sites#/sites/matthewherper/2015/09/24/my-lunch-with-shkreli-what-we-should-learn-from-pharmas-latest-monster/